S'abonner

Identification of novel immune phenotypes for allergic and nonallergic childhood asthma - 06/01/15

Doi : 10.1016/j.jaci.2014.07.046 
Diana Raedler, PhD a, Nikolaus Ballenberger, PhD a, Elisabeth Klucker, MD a, Andreas Böck, PhD a, Ragna Otto, MD a, Olivia Prazeres da Costa b, Otto Holst, PhD c, Thomas Illig, PhD d, e, f, Thorsten Buch, PhD b, Erika von Mutius, MD a, Bianca Schaub, MD a,
a University Children's Hospital Munich, the Department of Pulmonary & Allergy, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany 
b Institute for Medical Microbiology, Immunology and Hygiene, TUM Munich, Munich, Germany 
c Division of Structural Biochemistry, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Borstel, Germany 
d Institute of Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany 
e Hannover Unified Biobank, Hannover Medical School, Hannover, Germany 
f German Center for Lung Research (DZL), Hannover, Germany 

Corresponding author: Bianca Schaub, MD, University Children's Hospital Munich, LMU Munich, Lindwurmstr 4, 80337 Munich, Germany.

Abstract

Background

Childhood asthma is classified into allergic asthma (AA) and nonallergic asthma (NA), yet both are treated identically, with only partial success.

Objective

We sought to identify novel immune phenotypes for childhood AA and NA.

Methods

The Clinical Asthma Research Association cohort study includes 275 steroid-naive 4- to 15-year-old German children (healthy control subjects [HCs], patients with AA, and patients with NA). In PBMCs both quantitative and functional analysis of regulatory T (Treg) and TH17 cells (flow cytometry/Treg cell suppression) before/after anti-CD3/CD28, lipid A, and peptidoglycan stimulation were performed. Cytokines and gene expression, as assessed by using Luminex or transcriptomics/quantitative real-time RT-PCR, were analyzed by means of regression analysis. Linear discriminant analysis was applied to discriminate between phenotypes.

Results

The 3 phenotypes were immunologically well discriminated by means of microarray and protein analysis with linear discriminant analysis. Patients with AA were characterized by increased Treg cells compared with those in HCs but not those in patients with NA. Treg cells from patients with AA, but not patients with NA, significantly suppressed IL-5, IL-13, and IFN-γ secretion. Patients with AA had decreased expression of chloride intracellular channel 4 (CLIC4) and tuberous sclerosis 1 (TSC1), important innate immunity regulators. Patients with NA were characterized by increased proinflammatory IL-1β levels, neutrophil counts, and IL-17–shifted immunity. In parallel, expressions of anti-inflammatory IL37, proline-serine-threonine phosphatase–interacting protein 2 (PSTPIP2), and the neutrophil-associated genes CD93, triggering receptor expressed on myeloid cells 1 (TREM1), and regulator of G-protein signaling 13 (RGS13) were increased in patients with NA. A shared TH2 immunity was present in both asthma phenotypes.

Conclusion

Novel immune-regulatory mechanisms in childhood asthma identified increased Treg cells in patients with AA compared with those in HCs but not those in NA and decreased innate immunity genes for patients with AA, the first potentially indicating a counterregulatory mechanism to suppress cytokines yet not sufficient to control allergic inflammation. Very distinctly, patients with NA showed an IL-17–shifted proinflammatory immunity, promoting neutrophil inflammation and less functional Treg cells. Identification of these unique pathways provides a profound basis for future strategies for individualized prediction of asthma development, disease course, and prevention.

Le texte complet de cet article est disponible en PDF.

Key words : Childhood asthma phenotypes, immune-regulatory mechanisms, innate immunity, linear discriminant analysis, peripheral blood mononuclear cells, regulatory T cells, transcriptomics

Abbreviations used : AA, ATS, CLIC4, EIF4B, ERS, FOXP3, HC, ILC2, LDA, LpA, PSTPIP2, qRT-PCR, RGS13, Treg, TREM1, TSC1


Plan


 Supported by the German Research Foundation (DFG, TRR 22/2 and 22/3, SFB-TR22; to D.R., N.B., E.K., A.B., B.S., O.P.d.C., and T.B.), GPA, WAO (to B.S.), a grant from GlaxoSmithKline, Forschungsstipendium für Klinische Pneumologie 2013 (D.R.), FöFoLe Reg.Nr. 839 (DR), and the German Centre for Lung Research (DZL) as part of the Comprehensive Pneumology Centre in Munich (CPC-M; to D.R., B.S., and E.v.M.).
 Disclosure of potential conflict of interest: T. Buch has received research support from DFG, is employed by the Technical University of Munich, and has stock in biotechs within ETFs. E. von Mutius is an Associate Editor for the Journal of Allergy and Clinical Immunology; has consultant arrangements with GlaxoSmithKline, Novartis, ALK-Abelló, and Astellas Pharma Europe Ltd; has provided expert testimony for the UK Research Excellence Framework; and has received research support from FrieslandCampina. B. Schaub has received research support from DFG and is employed by University Children's Hospital Munich. The rest of the authors declare that they have no relevant conflicts of interest.


© 2014  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 135 - N° 1

P. 81-91 - janvier 2015 Retour au numéro
Article précédent Article précédent
  • Comparison of US emergency department acute asthma care quality: 1997-2001 and 2011-2012
  • Kohei Hasegawa, Ashley F. Sullivan, Yusuke Tsugawa, Stuart J. Turner, Susan Massaro, Sunday Clark, Chu-Lin Tsai, Carlos A. Camargo, MARC-36 Investigators ?
| Article suivant Article suivant
  • Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma
  • Russell S. Traister, Crystal E. Uvalle, Gregory A. Hawkins, Deborah A. Meyers, Eugene R. Bleecker, Sally E. Wenzel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.